Assessing Ketorolac (Toradol) at Oocyte Retrieval

Launched by SHADY GROVE FERTILITY REPRODUCTIVE SCIENCE CENTER · Aug 30, 2023

Keywords

ClinConnect Summary

This clinical trial is studying whether a medication called Ketorolac (also known as Toradol) can help manage pain and reduce the need for stronger painkillers after women have their eggs retrieved during fertility treatments. The goal is to see if using this nonsteroidal anti-inflammatory drug (NSAID) can improve the experience for patients undergoing oocyte retrieval, which is an important step in in vitro fertilization (IVF).

To participate in this study, women must be 18 years or older and scheduled for an egg retrieval procedure. They should be able to understand English or have a translator available. However, this trial is not for everyone; those with allergies to Ketorolac, certain medical conditions, a high body mass index (BMI), or a history of substance abuse will not be eligible. If you choose to participate, you'll be helping researchers learn more about effective pain management after this procedure, which could benefit many women in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Signed informed consent
• • 2. Females over 18 years of age who are scheduled to undergo oocyte retrieval
• • 3. Patients must be able to read and understand written English or have an appropriate certified medical translator available.
• • 4. Standard eligibility criteria to undergo IVF and embryo transfer at Shady Grove
• Exclusion Criteria:
• • 1. Known allergy to ketorolac
• • 2. Those with known medical conditions precluding them from ketorolac use (active peptic ulcer disease, recent or history of hemorrhage or perforation, known renal or hepatic insufficiency, suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, bleeding disorders, recent myocardial infarction, or stroke.)
• • 3. BMI ≥ 40 kg/m2
• • 4. History of substance abuse
• • 5. Chronic opioid use
• • 6. Transabdominal oocyte retrieval